Back to School: How biopharma can reboot drug development. Access exclusive analysis here

The reality of a virtual company

The reality of a virtual company

One way to save on overhead is to have none at all. Gary Snable is pushing that concept to the limit at Layton BioScience Inc., where he is president and CEO and the only employee.

While some biotech companies have been pressured to outsource work to manage cash, Layton's business plan is based on bootstrapping from the

Read the full 623 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE